World News – AU – The Serum Institute’s vaccine is being considered for emergency approval today

IANS |
New Delhi
Last updated on 30. December 2020 at 3:00 p.m.

The Central Drug Standard Control Organization (CDSCO) committee of experts will meet anytime on Wednesday to review the Serum Institute of India’s application for approval to approve its emergency Covid-19 vaccine, a senior government official said.

Development came after the UK became the first country in the world to approve a coronavirus vaccine developed by Oxford University and AstraZeneca, despite battling the new highly contagious variant of the coronavirus. document. write («  »); googletag. cmd. push (function () {googletag. defineOutOfPageSlot (‘/ 6516239 / outofpage_1x1_desktop’, ‘div-gpt-ad-1490771277198-0’). addService (googletag. pubads ()); googletag. Pubads (). enableSyncRendering (); googletag. enableServices ();});

The panel of experts will consider Adar Poonawalla’s Pune Company, which worked with Oxford University and AstraZeneca to manufacture the vaccine, for approval for emergency use.

Earlier this month, the CDSCO recommended SII to submit the outcome of the UK-MHRA assessment for EUAs, updated safety data from the Phase II / III clinical trial and immunogenicity data from the UK and India clinical trial in order to obtain approval.

The central government plans to vaccinate nearly 30 million people in the first phase of the journey. It is offered to a Crore health staff as well as 2 Crore Frontline and Essential employees and 27 Crore older people, who are mostly older than 50 years and suffer from comorbidities.

India currently has eight Covid-19 vaccine candidates, including three domestic vaccines, in various stages of clinical trials that could be ready for approval in the near future.

In addition to Covishield from the Serum Institute-Oxford, the Covaxin and Pfizer vaccines from Bharat Biotech are also in the battle for emergency approval.

(It is possible that only the headline and image of this report have been revised by the Business Standard staff. The rest of the content is automatically generated from a syndicated feed. )

Business Standard has always endeavored to provide updated information and commentary on developments that are of interest to you and have a wider political and economic impact on the country and the world. Your encouragement and constant feedback to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these troubled times resulting from Covid-19, we continue to strive to keep you updated with credible news, authoritative views, and concise comments on relevant topics.
However, we have a request.

As we struggle against the economic impact of the pandemic, we need your support even more so we can continue to offer you higher quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. A larger subscription to our online content can only help us achieve our goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

Business Standard would be happy to inform you about the introduction of « Business Standard Premium Services »

As a Premium subscriber, you get unrestricted access to a range of services across all devices, including:

Welcome to Business Standard Premium Services, courtesy of FIS.
Please visit the Manage My Subscription page to discover the benefits of this program.
Have fun while reading!
Team Business Standard

Serum Institute of India, Vaccine, India, Adar Poonawalla, Pneumococcal Vaccine, AstraZeneca, Coronavirus